FY26 Results
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The company reported a significant improvement in underlying earnings, although it faced a reported EBITDA loss due to increased operational costs. Looking ahead, Bubs anticipates improved momentum in the upcoming half-year, with expectations of positive revenue growth across various regions, particularly in the United States. The filing emphasizes the company's commitment to finalizing FDA approval to support its long-term growth ambitions in the U.S. market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/fy26-results-5
Earlier from Bubs Australia
- FY26 Trading Update
- Bubs Australia - Half Year Results Presentation
- Bubs Australia - Half Year Results Commentary
- Bubs Australia - Half Year Report and Appendix 4D
- Quarterly Activities/Appendix 4C Cash Flow Report
Later from Bubs Australia
- FY26 Appendix 4E and Preliminary Annual Report
- FY26 Results Presentation
- Bubs Secures Permanent US FDA Approval for Infant Formula
Follow Bubs Australia into a list and get an email when it puts out news.
Follow Bubs Australia